- Highlights Philips Azurion, the next generation image
guided therapy platform to optimize system integration and lab
performance
- Launches unique portfolio of iFR co-registration
technologies, including iFR Roadmap and SyncVision, to enhance
stenting strategies and patient care
AMSTERDAM, May 16, 2017 /PRNewswire/ -- Royal Philips
(NYSE: PHG, AEX: PHIA) will showcase its market-leading image
guided therapy solutions at EuroPCR 2017 (Paris, May 16 –
19, 2017) to advance interventional cardiology and make care more
personalized, while optimizing patient care and hospital budgets.
This year, the healthcare industry is celebrating the
40th anniversary of angioplasty, the minimally invasive
treatment of obstructed blood vessels, and as a leader in
interventional cardiology, Philips is reinforcing its longstanding
commitment to transforming cardiac care with meaningful
innovations.
Philips offers integrated solutions comprising interventional
X-ray imaging systems, planning and navigation software combined
with interventional devices - including IVUS and iFR technologies
for imaging and measurements from within the blood vessel - and a
broad range of services, all aimed at helping clinicians to provide
superior care at predictable costs.
Complementing this suite of technologies, Philips will introduce
its iFR Roadmap* technology, exclusive to Philips' interventional
labs, which enables physicians to navigate vessels and coronary
arteries in real time, guiding decision making in the treatment of
coronary artery disease. Philips will also present its SyncVision
iFR co-registration solution, which coupled with CORE IVUS and
Physiology technology, can be utilized in the stenting process when
lesions are more complex. SyncVision can be used in any
interventional lab to map pressure gradients onto the angiogram for
precise lesion location, severity and length measurements.
"As we celebrate 40 years of innovation in angioplasty, it's
incredible to see how far we've come," said Ronald Tabaksblat,
business leader Image Guided Therapy Systems. "From guiding the
first balloon angioplasty catheters to aiding state-of-the-art
interventions of today, and tomorrow, with the introduction of
Philips Azurion, our next-generation image guided therapy platform.
We are dedicated to dramatically transforming our technologies to
better address physician and patient needs. At EuroPCR, we're
demonstrating this commitment with our integrated solutions that
seamlessly connect people, technologies, and care protocols across
the health continuum."
As well as exhibiting its latest solutions in coronary artery
disease, Philips will showcase its technologies for
delivering diagnostic confidence and decision-making throughout the
cardiology patient journey, including:
- IntelliSpace Portal 9.0 – The latest edition of its
comprehensive, advanced visual analysis and quantification
platform, featuring a suite of multi-modality functions and
expanded neurological tools.
- DoseWise Portal 2.2 – A next-generation radiation dose
management software platform allowing physicians to record, track
and analyse radiation exposure to patients and clinicians.
- Dynamic Coronary Roadmap – Automatic, real-time
navigational guidance designed for procedure efficiency in complex
PCI interventions without changing current standard workflow.
- StentBoost Live – Instantaneous enhanced live
visualization, to position and deploy balloons, stents and
bioresorbable vascular scaffolds, reducing overall procedure
time.
Additionally, at the EuroPCR session on late-breaking clinical
trials today, the results of a meta-analysis of the DEFINE FLAIR
and iFR Swedeheart studies were presented, indicating that one-year
major adverse cardiac events (MACE) rates, when deferring treatment
based on instant wave-free ratio (iFR) guidance, are not
significantly different in patients presenting with either acute
coronary syndrome (ACS) or stable coronary disease (SCD). The
results of the meta-analysis also indicate that when deferring
patients, fractional flow reserve (FFR) is associated with higher
one-year MACE rates in ACS patients than in SCD patients. The
pooled data indicate that an iFR-guided strategy is associated with
consistent outcomes in ACS and SCD patients who were deferred from
treatment in the DEFINE FLAIR and iFR Swedeheart studies.
Along with the presentation of new iFR outcome data during the
show, in the Training Village Philips will host a series of
hands-on experiences and live demonstrations of key Philips
technologies. To recognize the ongoing efforts of radiographers to
promote radiation dose management awareness, Philips and the
International Society of Radiographers & Radiological
Technologists (ISRRT) will accept submissions for the next
"Radiographer of the Year" award. For more information, visit the
contest web page.
Visit Philips' booth (M71 on level 2) at EuroPCR 2017 and follow
demonstrations at the Azurion Experience Booth (F18 on level 1) or
visit the Philips event page. Follow the #EuroPCR and #FutureOfIGT
conversation via @PhilipsLiveFrom and @PhilipsHealth.
*1. iFR Roadmap is not a standalone technology. It can
only be purchased as part of the Dynamic Coronary Roadmap package.
2. iFR Roadmap is not yet CE marked and not yet available for
delivery.
For further information, please contact:
Alicia Cafardi
Philips Group Press Office
Tel: +1 412-523-9616
E-mail: Alicia.Cafardi@philips.com
Fabienne van der Feer
Philips Image Guided Therapy
Tel: +31 6-22698001
E-mail: fabienne.van.der.feer@philips.com
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, image-guided therapy, patient monitoring and
health informatics, as well as in consumer health and home care.
Philips' health technology portfolio generated 2016 sales of
EUR 17.4 billion and employs
approximately 70,000 employees with sales and services in more than
100 countries. News about Philips can be found at
www.philips.com/newscenter.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-showcases-new-integrated-image-guided-therapy-solutions-at-2017-europcr-to-transform-cardiac-care-and-help-improve-patient-care-300458290.html
SOURCE Royal Philips